Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2011, 4(10), 1328-1354; doi:10.3390/ph4101328
Review

Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy

1,* , 1, 1, 1, 1, 1, 1, 1 and 1,2,*
Received: 21 September 2011; in revised form: 27 September 2011 / Accepted: 30 September 2011 / Published: 13 October 2011
(This article belongs to the Special Issue Advances in Drug Design)
View Full-Text   |   Download PDF [1239 KB, uploaded 13 October 2011]
Abstract: Ribonucleotide reductase (RR) is a crucial enzyme in de novo DNA synthesis, where it catalyses the rate determining step of dNTP synthesis. RRs consist of a large subunit called RR1 (α), that contains two allosteric sites and one catalytic site, and a small subunit called RR2 (β), which houses a tyrosyl free radical essential for initiating catalysis. The active form of mammalian RR is an anbm hetero oligomer. RR inhibitors are cytotoxic to proliferating cancer cells. In this brief review we will discuss the three classes of RR, the catalytic mechanism of RR, the regulation of the dNTP pool, the substrate selection, the allosteric activation, inactivation by ATP and dATP, and the nucleoside drugs that target RR. We will also discuss possible strategies for developing a new class of drugs that disrupts the RR assembly.
Keywords: ribonucleotide reductase; gemcitabine; clofarabine; cladrabine; P6; P7; Cyc 10; dATP; ATP; allosteric regulation; specificity cross-talk; nucleotides ribonucleotide reductase; gemcitabine; clofarabine; cladrabine; P6; P7; Cyc 10; dATP; ATP; allosteric regulation; specificity cross-talk; nucleotides
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Wijerathna, S.R.; Ahmad, M.F.; Xu, H.; Fairman, J.W.; Zhang, A.; Kaushal, P.S.; Wan, Q.; Kiser, J.; Dealwis, C.G. Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy. Pharmaceuticals 2011, 4, 1328-1354.

AMA Style

Wijerathna SR, Ahmad MF, Xu H, Fairman JW, Zhang A, Kaushal PS, Wan Q, Kiser J, Dealwis CG. Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy. Pharmaceuticals. 2011; 4(10):1328-1354.

Chicago/Turabian Style

Wijerathna, Sanath R.; Ahmad, Md. Faiz; Xu, Hai; Fairman, James W.; Zhang, Andrew; Kaushal, Prem Singh; Wan, Qun; Kiser, Jianying; Dealwis, Chris G. 2011. "Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy." Pharmaceuticals 4, no. 10: 1328-1354.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert